News
![]() |
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 30, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today...
-
Aug 7, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry...
-
Aug 1, 2024
12-month data demonstrated regulation of iron levels, which aligns with improved ALS survival and disease mitigation Previous results showed PrimeC slowed disease progression by 36% and improved...
-
Jul 9, 2024
NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical...
-
Jul 1, 2024
Disease progression was slowed by 36% (p=0.009) in participants who received PrimeC for 12 months compared to those who initially received a placebo Consistent data across multiple endpoints...
-
Jun 24, 2024
Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term CAMBRIDGE, Mass., June 24, 2024...
-
Jun 21, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces that it has received a notice of delisting from...
-
May 20, 2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will...
-
May 14, 2024
PhaseV's Causal Machine Learning Predicts High Probability of Success in Multiple ALS Subgroups for NeuroSense's Phase 3 Trial CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- NeuroSense...
-
May 7, 2024
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patients Consistent data across subgroups underscore the potential of PrimeC to redefine the ALS treatment paradigm...
-
May 2, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update. Corporate Highlights from...
-
Apr 22, 2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD)...
-
Apr 18, 2024
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels CAMBRIDGE, Mass.
-
Apr 12, 2024
Emerging Science (Late-Breaker Equivalent) Abstract To Be Presented At 5:30PM Local Time Highlights Phase 2 PARADIGM Outcomes CAMBRIDGE, Mass., April 12, 2024 /PRNewswire/ -- NeuroSense...
-
Apr 10, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a...
-
Apr 9, 2024
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method...
-
Apr 5, 2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended...
-
Feb 21, 2024
PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFRS-R already demonstrated a statistically...
-
Feb 7, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock...
-
Jan 9, 2024
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE,...
-
Dec 27, 2023
This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass., Dec. 27, 2023 /PRNewswire/ -- NeuroSense...
-
Dec 14, 2023
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP)...
-
Dec 5, 2023
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a...
-
Dec 4, 2023
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...
-
Nov 28, 2023
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial,...
-
Nov 13, 2023
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
-
Nov 9, 2023
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass., Nov. 9, 2023...
-
Nov 6, 2023
Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to...
-
Nov 1, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik will...
-
Oct 17, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...
-
Oct 4, 2023
In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing...
-
Oct 2, 2023
Topline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024 CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ --...
-
Sep 20, 2023
SME status offers regulatory guidance and engagement in dialogue with EMA NeuroSense to open an EU office in Ulm, Germany Company plans to enroll patients at multiple sites across Europe in its...
-
Sep 19, 2023
Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)...
-
Sep 14, 2023
Company to deliver poster presentation regarding its PARADIGM Phase 2b ALS study at NEALS CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
-
Sep 6, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts are invited to register for the webinar event. CAMBRIDGE, Mass., Sept. 6, 2023...
-
Aug 16, 2023
ALS Phase 2b PARADIGM Trial Completed Patient Enrollment Topline results expected in Q-4 2023 Cash runway beyond topline clinical study readouts, into Q-2 2024 CAMBRIDGE, Mass., Aug. 16, 2023...
-
Jul 17, 2023
Investors interested in meeting the executive team and hearing NeuroSense's strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023...
-
Jul 11, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in two upcoming conferences...
-
Jul 6, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...
-
Jun 22, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase...
-
Jun 1, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended March 31,...
-
May 15, 2023
96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023 CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/...
-
May 2, 2023
Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals NeuroSense's...
-
Apr 17, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the...
-
Mar 27, 2023
In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results...
-
Mar 23, 2023
Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept...
-
Mar 22, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing...
-
Mar 16, 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik and...
-
Mar 14, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest...
-
Feb 13, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO...
-
Feb 9, 2023
QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept...
-
Feb 8, 2023
PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023 CAMBRIDGE, Mass., Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
-
Feb 6, 2023
Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass., Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd....
-
Jan 19, 2023
Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study...
-
Dec 1, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended...
-
Nov 16, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian...
-
Nov 15, 2022
NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which...
-
Oct 27, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences....
-
Oct 21, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering...
-
Oct 18, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and...
-
Oct 12, 2022
Investors and analysts interested in participating in the Summit via webinar may register here: LINK CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
-
Sep 29, 2022
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- NeuroSense...
-
Sep 28, 2022
Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously CAMBRIDGE, Mass., Sept. 28, 2022 /PRNewswire/...
-
Sep 21, 2022
Biomarker data to be presented provide indication of PrimeC's efficacy in ALS Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks Topline results expected...
-
Sep 20, 2022
PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome...
-
Sep 19, 2022
Groundbreaking ALS biomarker research: Marks the first publication of NeuroSense's novel biomarker results demonstrating PrimeC's effect on ALS related hallmarks PrimeC showed a statistically...
-
Aug 31, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June...
-
Aug 2, 2022
- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments - NeuroSense's CEO to present at EverythingALS's Expert Talk Series on...
-
Jul 28, 2022
NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to...
-
Jul 18, 2022
View video here: https://youtu.be/KCT2wzOqmNo CAMBRIDGE, Mass., July 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe...
-
Jun 30, 2022
Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease CogniC is expected to advance into clinical trials in 2023 CAMBRIDGE, Mass., June 30, 2022...
-
Jun 27, 2022
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline...
-
Jun 22, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's...
-
Jun 1, 2022
Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers PrimeC...
-
May 31, 2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March...
-
May 23, 2022
Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" Phase IIb ALS study for NeuroSense's combination...
-
Apr 11, 2022
Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- NeuroSense Therapeutics...
-
Apr 6, 2022
- Patent valid through 2038 - Phase IIb ALS trial expected to commence H1 2022 CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company...
-
Mar 30, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a video presentation with a corporate update from...
-
Mar 25, 2022
- Warrants exercised at $6 per share - Extends cash runway through Q3 2023 CAMBRIDGE, Mass., March 25, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company...
-
Mar 21, 2022- PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa study
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received clearance from the U.S. Food...
-
Mar 15, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that the company's CEO, Alon Ben-Noon, has been...
-
Mar 1, 2022- Patent valid through 2038
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the grant of a key patent in Australia. The...
-
Feb 24, 2022Presentation title: Breaking the Paradigm - PrimeC as a Novel Approach to ALS Therapy
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Dr. Shiran Zimri, the Company's Head of...
-
Feb 22, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it will present a company overview at the...
-
Jan 31, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Alon Ben-Noon, NeuroSenses's CEO will...
-
Jan 27, 2022- The new collaboration expands upon two successful partnered studies concluded in the recent year
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, announced today the initiation of the third stage of a collaborative...
-
Jan 4, 2022
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company's Phase IIa...
-
Dec 21, 2021- Upon closing its IPO the company appointed four new board members. Dr. Ferenc Tracik joined the company's senior management as Chief Scientific Officer.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the...
-
Dec 13, 2021
NeuroSense Therapeutics Ltd., (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating...
-
Dec 8, 2021
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as...
-
Oct 19, 2021NeuroSense filed the F-1 Registration Statement with the SEC on October 18th, 2021.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced...
-
Sep 29, 2021Mr. Leuchtenberger joins the company as a board member and chairperson, effective October 1, 2021.
NeuroSense Therapeutics, a clinical stage biotechnology company in the field of CNS, is pleased to announce the appointment of Mark Leuchtenberger as its new Chairman of the Board of Directors....
-
Mar 2, 2021The study's primary end-point was obtained successfully, and preliminary clinical signals were observed indicating that PrimeC could be an effective therapeutic for patients with ALS.
NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming...
-
Jan 12, 2021NeuroSense, a biotech company developing treatment for ALS, has been granted orphan designation for their first drug, PrimeC, from the European Medicines Agency.
NeuroSense Therapeutics, a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. Their treatment...
-
Nov 18, 2020Following 9-months of treatment with PrimeC, NeuroSense's combination drug, positive trends first seen in the 6-month interim analysis persist, indicating therapeutic potential for ALS patients.
NeuroSense Therapeutics, a biotech company developing PrimeC, a combination drug which aims to slow ALS progression, continues to report promising trends in their NST002 Phase IIa study, conducted...
-
Sep 9, 2020The clinical trial results demonstrate clearly that PrimeC, NeuroSense's combination drug, has significant therapeutic potential for amyotrophic lateral sclerosis (ALS) patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well tolerated in the interim analysis...
-
Feb 6, 2020The clinical trials initiated in the United States and in Israel will evaluate safety, tolerability and efficacy of PrimeC, NeuroSense's product for ALS patients.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow or halt ALS progression, announced today the initiation of two clinical studies to evaluate the...